O
Oculeve
Biotech & Life Sciences · San Francisco, United States · Founded 2011
Biotech company focused on developing novel treatments for dry eye MoreLess
Oculeve, a subsidiary of Allergan, specializes in developing innovative treatments for dry eye disease through advanced neurostimulation technology. The company primarily serves patients suffering from chronic dry eye conditions, a prevalent issue in the ophthalmology market. Oculeve operates within the healthcare sector, focusing on medical devices and therapeutic solutions. Its business model revolves around the research, development, and commercialization of its proprietary neurostimulation devices, which are designed to stimulate the lacrimal gland and increase tear production. Revenue is generated through the sale of these medical devices to healthcare providers and directly to patients. The company leverages its strong R&D capabilities and strategic partnerships to maintain a competitive edge in the market.
Keywords: dry eye disease, neurostimulation, ophthalmology, medical devices, lacrimal gland, tear production, healthcare, therapeutic solutions, R&D, commercialization.
Company overview
Oculeve company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2011
- Headquarters
- San Francisco, United States
- Employees
- 2
- Open positions
- None listed
- Dealroom signal
- 55.4
Valuation & funding
Oculeve funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jul 2015 | $125M | $125M | Allergan | — |
| LATE VC✓Equity / VC | Mar 2014 | $17M | $66M | NEA · Kleiner Perkins | — |
| EARLY VC✓Equity / VC | Mar 2013 | $7.6M | $30M | Kleiner Perkins · NEA | — |
| EARLY VC✓Equity / VC | Oct 2012 | $7.6M | $30M | Kleiner Perkins · NEA | — |
| DEBT✓Debt | May 2012 | $500K | — | Undisclosed | — |
| SPINOUT✓Other financing | Jan 2011 | Stanford University | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 2 |
| 2025 | 2 |
| 2024 | 2 |
| 2023 | 2 |
| 2022 | 2 |
| 2021 | 2 |
Growth signals
Oculeve website traffic
Latest recorded traffic for Oculeve is 180 monthly website visits. Oculeve's team grew 0% over the past year.
Comparisons
Oculeve compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Oculeve's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Oculeve has talent and traffic
team presence
In the news
Latest news about Oculeve
Recent press, funding announcements, and product moves mentioning Oculeve — open to read from the original sources.
Market sentiment
What the market is saying about Oculeve
An AI-synthesized read of the highest-engagement posts about Oculeve on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Oculeve’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.